Cargando…

An Accurate Definition of the Status of Inactive Hepatitis B Virus Carrier by a Combination of Biomarkers (FibroTest-ActiTest) and Viral Load

BACKGROUND: The combination of transaminases (ALT), biopsy, HBeAg and viral load have classically defined the inactive status of carriers of chronic hepatitis B. The use of FibroTest (FT) and ActiTest (AT), biomarkers of fibrosis and necroinflammatory activity, has been previously validated as alter...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ngo, Yen, Benhamou, Yves, Thibault, Vincent, Ingiliz, Patrick, Munteanu, Mona, Lebray, Pascal, Thabut, Dominique, Morra, Rachel, Messous, Djamila, Charlotte, Frederic, Imbert-Bismut, Françoise, Rousselot-Bonnefont, Dominique, Moussalli, Joseph, Ratziu, Vlad, Poynard, Thierry
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2008
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2440801/ https://www.ncbi.nlm.nih.gov/pubmed/18596917 http://dx.doi.org/10.1371/journal.pone.0002573

Ejemplares similares

Correction: An Accurate Definition of the Status of Inactive Hepatitis B Virus Carrier by a Combination of Biomarkers (FibroTest-ActiTest) and Viral Load
por: Ngo, Yen, et al.
Publicado: (2008)

Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C
por: Poynard, Thierry, et al.
Publicado: (2004)

Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest)
por: Munteanu, Mona, et al.
Publicado: (2004)

A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease
por: Halfon, Philippe, et al.
Publicado: (2002)

Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference
por: Munteanu, M., et al.
Publicado: (2016)

Meta-analyses of FibroTest diagnostic value in chronic liver disease
por: Poynard, Thierry, et al.
Publicado: (2007)

Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest)
por: Poynard, Thierry, et al.
Publicado: (2010)

Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease
por: Ratziu, Vlad, et al.
Publicado: (2006)

Performance of Biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in Patients with Severe Obesity: Meta Analysis of Individual Patient Data
por: Poynard, Thierry, et al.
Publicado: (2012)

Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age
por: Poynard, Thierry, et al.
Publicado: (2011)

Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus
por: Bril, Fernando, et al.
Publicado: (2019)

Concordance in a World without a Gold Standard: A New Non-Invasive Methodology for Improving Accuracy of Fibrosis Markers
por: Poynard, Thierry, et al.
Publicado: (2008)

Long‐term prognostic value of the FibroTest in patients with non‐alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease
por: Munteanu, Mona, et al.
Publicado: (2018)

Assessment of Liver Fibrosis: Noninvasive Means
por: Poynard, Thierry, et al.
Publicado: (2008)

Noninvasive biomarkers FibroTest and ActiTest versus liver biopsy in chronic hepatitis C patients: the Middle East experience
por: Yakoob, Rafie, et al.
Publicado: (2015)

Non-invasive evaluation of the liver disease severity in children with chronic viral hepatitis using FibroTest and ActiTest – comparison with histopathological assessment
por: Pokorska-Śpiewak, Maria, et al.
Publicado: (2017)

Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease
por: Poynard, Thierry, et al.
Publicado: (2006)

Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis
por: Friedrich-Rust, Mireen, et al.
Publicado: (2010)

The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis
por: Poynard, Thierry, et al.
Publicado: (2005)

Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia
por: Poynard, Thierry, et al.
Publicado: (2023)

Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis
por: Rudler, Marika, et al.
Publicado: (2015)

Discordance between Liver Biopsy and FibroTest in Assessing Liver Fibrosis in Chronic Hepatitis B
por: Park, Mi Sung, et al.
Publicado: (2013)

LCR1 and LCR2, two multi‐analyte blood tests to assess liver cancer risk in patients without or with cirrhosis
por: Poynard, Thierry, et al.
Publicado: (2018)

Hirsch Index and Truth Survival in Clinical Research
por: Poynard, Thierry, et al.
Publicado: (2010)

Prospective Validation of ELF Test in Comparison with Fibroscan and FibroTest to Predict Liver Fibrosis in Asian Subjects with Chronic Hepatitis B
por: Kim, Beom Kyung, et al.
Publicado: (2012)

Prospective Validation of FibroTest in Comparison with Liver Stiffness for Predicting Liver Fibrosis in Asian Subjects with Chronic Hepatitis B
por: Kim, Beom Kyung, et al.
Publicado: (2012)

FibroTest for Evaluating Fibrosis in Non-Alcoholic Fatty Liver Disease Patients: A Systematic Review and Meta-Analysis
por: Vali, Yasaman, et al.
Publicado: (2021)

Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery
por: Peta, Valentina, et al.
Publicado: (2017)

Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B
por: Poynard, Thierry, et al.
Publicado: (2011)

Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes
por: Poynard, Thierry, et al.
Publicado: (2019)

Resveratrol and Cardiovascular Diseases
por: Bonnefont-Rousselot, Dominique
Publicado: (2016)

Successful rescue therapy with tenofovir in a patient with hepatic decompensation and adefovir resistant HBV mutant
por: Ratziu, Vlad, et al.
Publicado: (2006)

UCx Prototype Target Tests for ActiLab-ENSAR
por: Andrighetto, A; INFN-LNL, et al.
Publicado: (2011)

UC$_{x}$ prototype target tests for ActiLab-ENSAR
por: Andrighetto, A, et al.
Publicado: (2012)

Real Time Identification of Drug-Induced Liver Injury (DILI) through Daily Screening of ALT Results: A Prospective Pilot Cohort Study
por: M'Kada, Helmi, et al.
Publicado: (2012)

Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19
por: Deckmyn, Olivier, et al.
Publicado: (2022)

Performance of serum apolipoprotein-A1 as a sentinel of Covid-19
por: Poynard, Thierry, et al.
Publicado: (2020)

Laudator Temporis Acti
Publicado: (1905)

Broad-spectrum antimicrobial activity of wetland-derived Streptomyces sp. ActiF450
por: Benhadj, Mabrouka, et al.
Publicado: (2020)

Impact of steatosis and inflammation definitions on the performance of NASH tests
por: Poynard, Thierry, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_dctngb7cm0c1g8suimeard354n